Related Experiment Video

Updated: Jun 20, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Bcl-2 modulation to activate apoptosis in prostate cancer

Kevin Bray1, Hsin-Yi Chen, Cristina M Karp

  • 1The Cancer Institute of New Jersey, New Brunswick, NJ 08903-2681, USA.

Molecular Cancer Research : MCR
|September 10, 2009
PubMed

Insights

Targeting Bcl-2 and Mcl-1 overcomes apoptosis resistance in prostate cancer. Combining therapies promotes cell death, offering a potential strategy for advanced disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Apoptosis resistance is a key factor in cancer progression and treatment failure.
  • Overexpression of antiapoptotic Bcl-2 is common in refractory prostate cancer.
  • Bcl-2 antagonists like ABT-737 show limited efficacy due to Mcl-1 co-expression.

Purpose of the Study:

  • To investigate therapeutic strategies targeting apoptosis resistance in prostate cancer.
  • To evaluate the efficacy of combining Bcl-2 and Mcl-1 inhibition.
  • To assess the potential of combination therapy in preclinical models and human tissues.

Main Methods:

  • Development of a mouse model for prostate cancer with Bcl-2-driven apoptosis resistance.
  • In vitro studies combining ABT-737 with Mcl-1 targeting agents.
  • In vivo efficacy assessment of ABT-737 in prostate tumor allografts.
  • Evaluation of combination chemotherapy in a novel human tumor explant system (Tumor Tissue Assessment for Response to Chemotherapy).

Main Results:

  • Combined Bcl-2 and Mcl-1 targeting sensitized prostate cancer cells to apoptosis in vitro.
  • ABT-737 demonstrated single-agent efficacy in hypoxic prostate tumor allografts in vivo.
  • Combination chemotherapy induced efficient apoptosis in human prostate cancer tissues.

Conclusions:

  • Co-targeting Bcl-2 and Mcl-1 is a promising strategy for overcoming apoptosis resistance in prostate cancer.
  • Combination therapy may offer therapeutic advantages for advanced prostate cancer.
  • Novel therapeutic approaches are needed to address treatment resistance in prostate cancer.

More Related Videos

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...